DEpletion of Serum amyloid P component In Alzheimer's Disease: DESPIAD. Double-blind placebo controlled randomised phase IIb trial of SAP depletion by CPHPC in mild Alzheimer's disease.
Phase of Trial: Phase II
Latest Information Update: 02 Aug 2017
At a glance
- Drugs GSK 2315698 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- Acronyms DESPIAD
- 02 Aug 2017 Last checked against ISRCTN: Current Controlled Trials record.
- 02 Jul 2017 Status changed from not yet recruiting to recruiting.
- 24 May 2017 Status changed from planning to not yet recruiting.